Poolbeg Pharma commences trading on OTCQB Market in the United States
Poolbeg Pharma commences trading on OTCQB Market in the United States
31 January 2022 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical-stage infectious disease pharmaceutical company with a capital-light clinical model, confirms that it has signed the licence
Targeting the growing infectious disease market, we are developing multiple assets quickly to Phase II ready with plans to monetise early to Big Pharma. POLB spun out of Open Orphan
Share Talk caught up with our CEO to discuss yesterday’s announcement on #POLB’s has signed a binding term sheet, encompassing all commercial terms, with AnaBio Technologies (AnaBio), with a full
16 December, 2021- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has signed a binding term sheet,